BioNTech's Ugur Sahin and Özlem Türeci after receiving the Federal Cross of Merit, March 19, 2021 (Bernd von Jutrczenka/picture-alliance/dpa/AP Images)
March 30, 2021 08:26 AM EDTUpdated 08:40 AM
Coronavirus

BioN­Tech makes a splash with $10B+ pro­jec­tion for 2021 Covid-19 vac­cine sales

Zachary Brennan

Senior Editor

BioN­Tech, Pfiz­er’s rel­a­tive­ly qui­et Ger­man biotech part­ner for its Covid-19 vac­cine, made noise on Tues­day with its earn­ings re­port, pro­ject­ing about €10 bil­lion ($11.5 bil­lion) …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times